{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:17:44Z","timestamp":1786324664092,"version":"build-2736575974"},"reference-count":24,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,5,27]],"date-time":"2018-05-27T00:00:00Z","timestamp":1527379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Risk stratification for stroke in patients with atrial fibrillation is a vital step in identifying whether antithrombotic therapy is indicated for stroke prevention in this common arrhythmia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      The aim of this study was to determine adherence to guideline-directed antithrombotic therapy based on Congestive Heart Failure (1 point), Hypertension (1 point), Age (\u226575 years old is 2 points and 65-74 is 1 point), Diabetes (1 point), prior Stroke (2 points), Vascular Disease (1 point), and Sex Category (1 point if female; CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      \u2013VASc) score in patients with atrial fibrillation (AF) on hospital discharge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 293 patients discharged from this academic medical center with a history of atrial fibrillation from June 2014 to June 2016 were enrolled. Demographic data and indicators for antithrombotic therapy based on the CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      \u2013VASc score were recorded, and factors that affected adherence to guideline-directed therapy, such as bleeding risk, falls, and alcohol abuse, were collected and analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At hospital discharge, 63% of patients with AF were on appropriate antithrombotic therapy, 50% with a CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      \u2013VASc score \u22652. The odds ratio of appropriate therapy in patients with a CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      \u2013VASc score \u22652 was 1.17 (95% confidence interval [CI]: 0.95-1.30; P = .18). When chart documentation for reasons to withhold anticoagulation was considered as appropriate therapy, 81% of patients with AF were discharged on appropriate antithrombotic therapy with an odds ratio of 1.57 (95% CI: 1.26 -1.96, P &lt; .0001), with bleeding and falls risk as the most common reasons to withhold anticoagulation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Based on risk stratification of stroke through the CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      \u2013VASc score, the majority of patients with AF were discharged from the hospital on appropriate antithrombotic therapy. Withholding anticoagulation due to falls risk should be reconsidered as a result of the known benefits of stroke prevention in atrial fibrillation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1074248418778804","type":"journal-article","created":{"date-parts":[[2018,5,27]],"date-time":"2018-05-27T22:25:17Z","timestamp":1527459917000},"page":"502-508","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-1536","authenticated-orcid":false,"given":"Lori","family":"Dupree","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, UF Health Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marci","family":"DeLosSantos","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UF Health Jacksonville, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Smotherman","sequence":"additional","affiliation":[{"name":"Center for Health Equity and Quality Research, University of Florida, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,5,27]]},"reference":[{"issue":"4","key":"bibr1-1074248418778804","first-page":"443","volume":"9","author":"Heidenreich PA","year":"2016","journal-title":"Circulation"},{"key":"bibr2-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000140263.20897.42"},{"key":"bibr3-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31257-0"},{"key":"bibr4-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.12.013"},{"key":"bibr5-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000041"},{"key":"bibr6-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2015.0374"},{"key":"bibr7-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.1371"},{"key":"bibr8-1074248418778804","unstructured":"American Heart Association. Atrial fibrillation fact sheet. Get With the Guidelines\u2014AFIB. 2017. http:\/\/www.heart.org\/idc\/groups\/heart-public\/@private\/@wcm\/@hcm\/@gwtg\/documents\/downloadable\/ucm_451183.pdf. Accessed May 9, 2018."},{"key":"bibr9-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0134"},{"key":"bibr10-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.11.025"},{"key":"bibr11-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.07.019"},{"key":"bibr12-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)01109-9"},{"key":"bibr13-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.007864"},{"key":"bibr14-1074248418778804","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-11-199606010-00004"},{"key":"bibr15-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.12.018"},{"key":"bibr16-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.07.013"},{"key":"bibr17-1074248418778804","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.84a.16016"},{"key":"bibr18-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.7.677"},{"key":"bibr19-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.3057"},{"key":"bibr20-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K498"},{"key":"bibr21-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004834"},{"key":"bibr22-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"bibr23-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611594"},{"key":"bibr24-1074248418778804","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708454"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248418778804","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1074248418778804","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248418778804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:42:50Z","timestamp":1777394570000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1074248418778804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,27]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1177\/1074248418778804"],"URL":"https:\/\/doi.org\/10.1177\/1074248418778804","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,27]]}}}